-
公开(公告)号:US20170174652A1
公开(公告)日:2017-06-22
申请号:US15222523
申请日:2016-07-28
IPC分类号: C07D401/04 , C07D405/12 , C07D403/12 , C07D403/14 , C07D401/12 , C07D409/12 , C07D475/00 , C07D239/84 , C07D471/04
CPC分类号: C07D401/04 , C07D235/30 , C07D239/84 , C07D401/12 , C07D403/12 , C07D403/14 , C07D405/12 , C07D409/12 , C07D471/04 , C07D475/00
摘要: Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
-
公开(公告)号:US20170029409A1
公开(公告)日:2017-02-02
申请号:US15295450
申请日:2016-10-17
发明人: Lucian V. DiPietro , Brian L. Hodous , Joseph L. Kim , Chandrasekhar V. Miduturu , Steven Mark Wenglowsky , Douglas Wilson , Yulian Zhang
IPC分类号: C07D403/14 , C07D487/04 , C07D413/14 , C07D409/14 , C07D487/08 , C07D405/14 , C07D473/34 , C07D401/14
CPC分类号: C07D403/14 , C07D239/94 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D405/14 , C07D409/14 , C07D413/14 , C07D473/34 , C07D487/04 , C07D487/08 , C07D487/22
摘要: Compounds and compositions useful for treating disorders related to Kit are described herein.
摘要翻译: 本文描述了可用于治疗与Kit相关的疾病的化合物和组合物。
-
公开(公告)号:US10584114B2
公开(公告)日:2020-03-10
申请号:US16041719
申请日:2018-07-20
IPC分类号: C07D401/14 , C07D403/14
摘要: Described herein are compounds that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
-
公开(公告)号:US10030005B2
公开(公告)日:2018-07-24
申请号:US15340428
申请日:2016-11-01
IPC分类号: A61K31/506 , C07D401/14 , C07D403/14
摘要: Described herein are compounds that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
-
公开(公告)号:US10000490B2
公开(公告)日:2018-06-19
申请号:US15599006
申请日:2017-05-18
IPC分类号: C07D487/04 , C07D471/04 , C07D403/04 , A61K31/517 , A61P35/00 , C07D413/04 , C07D239/74 , C07D217/16 , C07D217/14 , C07D487/14
CPC分类号: C07D471/04 , A61K31/517 , C07D217/14 , C07D217/16 , C07D239/74 , C07D403/04 , C07D413/04 , C07D487/04 , C07D487/14
摘要: Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions to inhibit the activity of FGFR-4.
-
公开(公告)号:US10221154B2
公开(公告)日:2019-03-05
申请号:US15222523
申请日:2016-07-28
IPC分类号: C07D405/12 , C07D409/12 , A61K31/517 , C07D401/04 , C07D239/84 , C07D403/12 , C07D471/04 , C07D475/00 , C07D401/12 , C07D235/30 , C07D403/14
摘要: Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
-
公开(公告)号:US20170121312A1
公开(公告)日:2017-05-04
申请号:US15340428
申请日:2016-11-01
IPC分类号: C07D401/14
CPC分类号: C07D401/14 , C07D403/14
摘要: Described herein are compounds that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
-
公开(公告)号:US20220315560A1
公开(公告)日:2022-10-06
申请号:US17669785
申请日:2022-02-11
IPC分类号: C07D401/14 , C07D403/14 , C07D239/30 , C07D239/36
摘要: Described herein are compounds that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
-
公开(公告)号:US20210347756A1
公开(公告)日:2021-11-11
申请号:US17102628
申请日:2020-11-24
IPC分类号: C07D401/04 , C07D401/12 , C07D235/30 , C07D403/14 , C07D409/12 , C07D239/84 , C07D403/12 , C07D405/12 , C07D471/04 , C07D475/00
摘要: Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
-
公开(公告)号:US10202365B2
公开(公告)日:2019-02-12
申请号:US15548925
申请日:2016-02-05
发明人: Natasja Brooijmans , Lucian V. DiPietro , Paul E. Fleming , Joseph L. Kim , Steven Mark Wenglowsky , Yulian Zhang
IPC分类号: A61K31/506 , C07D401/14 , C07D403/12 , C07D405/14 , C07D403/04 , C07D417/14 , A61K45/06
摘要: Described herein are compounds, such as compounds of Formula (I) and pharmaceutically acceptable salts thereof, that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions, e.g., for treating a condition mediated by aberrant RET activity
-
-
-
-
-
-
-
-
-